First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumorsarticle Published on 2020-01-242024-09-02 Journal: Cancer Immunology, Immunotherapy [Category] 대상포진, [키워드] Cancer vaccine NOD2 NY-ESO-1 antigen TLR9 [DOI] 10.1007/s00262-020-02483-1 PMC 바로가기 [Article Type] article